J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depression

Delix Therapeutics has raised $100 million in a series C round backed by the likes of Johnson & Johnson to advance a phase 2-ready non-hallucinatory psychedelic therapy for depression.